PMID- 17086090
OWN - NLM
STAT- MEDLINE
DCOM- 20061204
LR  - 20181201
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 48
IP  - 4
DP  - 2006 Oct
TI  - The effect of angiotensin II receptor blockade on an end-stage renal failure 
      model of type 2 diabetes.
PG  - 135-42
AB  - The effect of olmesartan medoxomil (OLM), an angiotensin II receptor blocker 
      (ARB), on advanced nephropathy and mortality was evaluated in Zucker Diabetic 
      Fatty (ZDF) rats, a type 2 diabetes model. OLM was administered from 36 weeks of 
      age, when the animals developed advanced proteinuria. OLM effectively suppressed 
      the progression of proteinuria. The ZDF rats started to die at 50 weeks of age, 
      which was accompanied by abrupt increase in blood urea nitrogen, suggesting that 
      the cause of death was renal insufficiency. OLM suppressed increases in blood 
      urea nitrogen and increased the survival rate of the ZDF rats. The histological 
      examination revealed that the renal damage was ameliorated by OLM. The macrophage 
      infiltration and monocyte chemoattractant protein-1 (MCP-1) expression was 
      increased in the glomeruli and tubulointerstitium of the ZDF rat kidneys, and the 
      increase was lessened by OLM. In a separate study, albumin increased MCP-1 
      release from cultured tubular epithelial cells. These results suggest that 
      protein leakage from the glomeruli stimulates MCP-1 production in tubular cells 
      and that MCP-1 released into the interstitial space induces macrophage 
      infiltration and inflammation. It is conceivable that the beneficial actions of 
      ARB on diabetic nephropathy are, at least in part, due to decrease of proteinuria 
      and the subsequent reduction of inflammatory changes in tubular cells.
FAU - Mizuno, Makoto
AU  - Mizuno M
AD  - Pharmacodymanics Research Laboratories, the Pharmacology and Molecular Biology 
      Research Laboratories, and R&D Headquarters, Sankyo Co. Ltd., Tokyo, Japan.
FAU - Sada, Toshio
AU  - Sada T
FAU - Kato, Mikio
AU  - Kato M
FAU - Fukushima, Yasuo
AU  - Fukushima Y
FAU - Terashima, Hideki
AU  - Terashima H
FAU - Koike, Hiroyuki
AU  - Koike H
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Blood Glucose)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Imidazoles)
RN  - 0 (Lipids)
RN  - 0 (Serum Albumin)
RN  - 0 (Tetrazoles)
RN  - 6M97XTV3HD (Olmesartan Medoxomil)
RN  - AYI8EX34EU (Creatinine)
SB  - IM
MH  - Angiotensin II Type 1 Receptor Blockers/*therapeutic use
MH  - Animals
MH  - Blood Glucose/analysis
MH  - Blood Urea Nitrogen
MH  - Body Weight/drug effects
MH  - Chemokine CCL2/metabolism
MH  - Creatinine/blood
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Diabetic Nephropathies/*drug therapy
MH  - Imidazoles/*therapeutic use
MH  - Immunohistochemistry
MH  - Kidney Failure, Chronic/*drug therapy
MH  - Lipids/blood
MH  - Male
MH  - Olmesartan Medoxomil
MH  - Proteinuria/drug therapy
MH  - Rats
MH  - Serum Albumin/analysis
MH  - Survival Rate
MH  - Systole/drug effects
MH  - Tetrazoles/*therapeutic use
EDAT- 2006/11/07 09:00
MHDA- 2006/12/09 09:00
CRDT- 2006/11/07 09:00
PHST- 2006/11/07 09:00 [pubmed]
PHST- 2006/12/09 09:00 [medline]
PHST- 2006/11/07 09:00 [entrez]
AID - 00005344-200610000-00001 [pii]
AID - 10.1097/01.fjc.0000245241.79959.d6 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 2006 Oct;48(4):135-42. doi: 
      10.1097/01.fjc.0000245241.79959.d6.